Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052254 · ClinicalTrials.gov registry record · Phase 2
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
A Phase 2 study of Agitation, sponsored by Teikoku Pharma USA.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT06052254 is a Phase 2 study of Agitation that is actively recruiting participants, run by Teikoku Pharma USA. The registered enrollment target is 150 participants, below the 192-participant average among 8 other Agitation trials with a reported enrollment target (22% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06052254, a Phase 2 study of Agitation, is actively recruiting participants, sponsored by Teikoku Pharma USA.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.
Conditions Studied
Interventions
- DRUG 12 cm2 - 2 Active DMTS Patches
- DRUG 6 cm2 - 1 Active and 1 Placebo DMTS Patches
- DRUG Placebo - 2 Placebo DMTS Patches
Study Locations (3)
Massachusetts
- Elixia MA, LLC - Springfield
- Vitalix - Worcester
New Jersey
- BioBehavioral Health - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06052254
The ClinicalTrials.gov registry entry for NCT06052254 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 8 other Agitation trials with a reported enrollment target (22% lower). The listed sponsor is Teikoku Pharma USA, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Agitation appearing as the primary indexed condition, and to 3 interventions - of which 12 cm2 - 2 Active DMTS Patches is the first listed.
NCT06052254 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06052254 about?
NCT06052254 is a clinical study titled "Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type". The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.
What is the current status of trial NCT06052254?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-09-16. Estimated completion is 2027-01.
What conditions does trial NCT06052254 study?
This clinical trial studies the following conditions: Agitation.
What interventions are being tested in trial NCT06052254?
The interventions under investigation include: 12 cm2 - 2 Active DMTS Patches (DRUG), 6 cm2 - 1 Active and 1 Placebo DMTS Patches (DRUG), Placebo - 2 Placebo DMTS Patches (DRUG).
Who is sponsoring clinical trial NCT06052254?
This trial is sponsored by Teikoku Pharma USA, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06052254 being conducted?
This trial has 3 study locations across Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Agitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
ACTIVE NOT RECRUITING · Phase 2
-
Neurosteer Bedside Monitoring System
RECRUITING · NA
-
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
RECRUITING · Phase 3
-
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
RECRUITING · Phase 3
-
Helping Older Persons Emerge Stronger
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.